Citations

Clear

2303 citation(s) found for "Yu, Edward".

Quality Measures Addressing Disparities to Improve Outcomes in Hand Surgery
Schultz, Emily , Richard, Marc J. , Ruch, David S. , Ring, David , Kakar, Sanjeev , Got, Christopher, Akelman, Edward , Blazar, Philip E., Yao, Jeffrey, Sears, Erika D. , Schultz, Emily A , Ring, David , Kakar, Sanjeev , Sears, Erika D , Kamal, Robin N , Shapiro, Lauren M , Snyder, Eli M. , Richard, Marc J., Got, Christopher , Blazar, Philip , Yao, Jeffrey , Ladd, Amy L. , Kamal, Robin N.

Mayo Clinic

HAND | June 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15589447261453556 | PMID 42337843 Get It

Background: There is growing evidence that social determinants of health (SDOH) are associated with disparities in access to care and hand and upper extremity health. Quality measures represent an opportunity to evaluate disparities in access and outcomes that can inform improvement interventions. We performed a systematic review of evidence regarding health disparities within hand surgery and aimed to develop suitable quality measures that are clinically important, feasible, usable, and scientifically acceptable. Methods: We performed a systematic review including common hand surgery terms to identify health disparities in hand surgery related to SDOH. Candidate quality measures were constructed based upon evidence from the systematic review. A consortium of 11 US-based hand and upper extremity surgeons completed a modified RAND/UCLA Delphi Appropriateness process to evaluate the importance, feasibility, usability, and scientific acceptability of the candidate quality measures. Panelists rated each measure on a scale of 1 ( definitely not important/feasible/usable/scientifically acceptable ) to 9 ( definitely important/feasible/usable/scientifically acceptable ) in 2 voting rounds separated by a face-to-face discussion. Agreement among panelists and validity were assessed using predetermined criteria. Results: Fourteen candidate quality measures addressing health disparities were identified based on evidence from the systematic review, including time to surgery and emergency department use after hand surgery based on insurance type, clinical outcomes based on social deprivation, among others. All 14 measures were accepted. Conclusions: Fourteen candidate quality measures were identified and accepted based upon consensus to address health disparities in hand surgery, although future investigation will be needed to evaluate their effectiveness.
Editorial. Training pediatric neurosurgeons: but where in the world do they go?
Ahn, Edward S., Ahn, Edward S.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | June 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-2

10.3171/2026.1.peds25646 | PMID 42361365 Get It

Characterisation of Posterior Predominant Amyloid PET Binding Across Multiple Cohorts
Giorgio, Joseph , Landau, Susan, Yokoyama, Jennifer S. , Soleimani-Meigooni, David, Carrillo, Maria, Grinberg, Lea, Seeley, William W Tenenholz, Spina, Salvatore, Nudelman, Kelly, Apostolova, Liana, Dickerson, Bradford C, Jagust, William J, Rabinovici, Gil, Initiative, Alzheimer’s Disease Neuroimaging, Yokoyama, Jennifer , Blazhenets, Ganna , Landau, Susan , Pezzoli, Stefania , Seeley, William W. , Spina, Salvatore , Nudelman, Kelly , Dickerson, Bradford Clark , Jagust, William J. , Rabinovici, Gil D. , Joie, Renaud La , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

No container title available | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.17.733031 | PMID 42395404 Get It

Abstract The standard approach to quantify amyloid (Aβ) PET averages uptake within a single cortical mask that assumes no clinically relevant spatial heterogeneity in uptake patterns. Here, in a sample of 12,379 clinically impaired participants taken from four phenotypically diverse cohorts we use data-driven approaches to discover heterogeneous patterns of Aβ-PET binding, uncovering a reproducible and clinically relevant pattern of posterior predominant Aβ-PET binding. In particular, Aβ-PET positive participants who have posterior predominant binding are less likely to be APOE -ε4 carriers, more severely impaired, have thinner cortex in posterior regions, and greater posterior tau PET burden. Furthermore, in a subsample of participants with neuropathological assessment, participants with posterior predominant Aβ binding have a higher likelihood of having cerebral amyloid angiopathy at autopsy. These findings suggest that Aβ-PET accumulates along two orthogonal axes with biological and clinical relevance, indicating that the standard approach to assess Aβ-PET is insufficient to capture meaningful signal from Aβ-PET imaging. This work has implications for the diagnosis and treatment of Alzheimer’s disease and extends our understanding of the mechanisms governing variable Aβ-PET distribution and its downstream effects.
P257 Efficacy and safety up to 3 years of risankizumab in moderately to severely active ulcerative colitis patients: COMMAND interim results
Atreya, Raja, Louis, Edouard, Loftus, Edward V, Rubin, David T, Dubinsky, Marla C., Hisamatsu, T, Kalabic, Jasmina , Méndez, Paloma, Chen, S H, Shah, Saajan, Morisset, Pierre, Duan, W Rachel, Coll, Christina, Panaccione, Remo, Atreya, Raja Narayana , Rubin, David T. , Hisamatsu, Tadakazu, Mendez, Paloma, Morisset, Pierre, Duan, W Rachel, Panaccione, Remo

Mayo Clinic

E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A240.2-A241

10.1136/gutjnl-2026-bsg.373 Get It

P189 Efficacy and safety of upadacitinib maintenance treatment in patients with moderately to severely active crohn’s disease: 3-year results from U-ENDURE
Loftus, Edward V, D’Haens, Geert R, Louis, Edouard, Regueiro, Miguel D, Jairath, Vipul, Magro, Fernando, Nakase, Hiroshi, Dubcenco, Elena, Fish, Irina, Kim, Kimmie, Wang, Y , Anyanwu, Samuel I, Aponte, Fernando, Ogholikhan, Sina, Coll, Christina, Blumenstein, Irina, D’Haens, Geert R, Jairath, Vipul , Magro, F , Nakase, Hiroshi , Anyanwu, Samuel, Ogholikhan, Sina, Blumenstein, Irina

Mayo Clinic

E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A198.1-A198

10.1136/gutjnl-2026-bsg.315 Get It

P171 Efficacy and safety of icotrokinra, a targeted oral peptide that blocks il-23 receptor activation, in ulcerative colitis: results from ANTHEM-UC
Limdi, Jimmy, Jairath, Vipul, Siegmund, Britta, Surace, Lindsey, Erondu, Ngozi, Chen, Minhu, Chachu, Karen, Louis, Edouard, Matsuoka, Katsuyoshi, Houck, Nicole, Frustaci, Mary Ellen, Zhan, Joyce, Rydzewska, G, VLoftus, Edward, Abreu, M T, Jairath, Vipul , Siegmund, Britta, Erondu, Ngozi, Chachu, Karen A., Matsuoka, Katsuyoshi , Arthur, Edmund, Frustaci, Mary Ellen, Rydzewska-Wyszkowska, Grażyna

Mayo Clinic

E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A188-A188

10.1136/gutjnl-2026-bsg.299 Get It

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action
Graff‐Radford, Jonathan, Boon, Baayla D. C., Westman, Eric, Groot, Colin, Jones, David T., Grinberg, Lea T., Rabinovici, Gil D., Whitwell, J R, Apostolova, L G, Mj, Murray, Hammers, Dustin B., Schindler, Suzanne E., Atonsdottir, Inga, Schott, J J, Illán‐Gala, Ignacio, Chukwuanugo, Ogbuagu, Guerra, Jorge J. Llibre, Peters, Ruth, Abner, Erin L., Abdelnour, Carla , A, Cortes Llado, Joie, Renaud La, Souza, Leonardo Cruz de, Shir, Dror , Pijenburg, Yolande A. L., Carrillo, Maria C., Dickerson, Bradford C, Aisen, P, Ossenkoppele, Rik, Raman, Rema, Joie, Renaud La , Corriveau-Lecavalier, Nick , La Joie, Renaud , Shir, Dror , Corriveau‐Lecavalier, Nick , Falgàs, Neus , Putcha, Deepti , Graff‐Radford, Jonathan , Yong, Keir , Boon, Baayla D.C. , Mohanty, Rosaleena , Westman, Eric , Groot, Colin , Jones, David T. , Grinberg, Lea T. , Rabinovici, Gil D. , Whitwell, Jennifer L. , Apostolova, Liana G. , Hammers, Dustin B , Schindler, Suzanne E. , Rhodus, Elizabeth K. , Illán‐Gala, Ignacio , OGBUAGU, CHUKWUANUGO, Abner, Erin L. , Souza, Leonardo Cruz de , Rezaii, Neguine , Carrillo, María C. , Dickerson, Bradford Clark , Aisen, Paul , Ossenkoppele, Rik , Raman, Rema

Mayo Clinic

Alzheimer's & Dementia | June 23, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71521 | PMID 42334062 Get It

Abstract Patients with atypical variants of Alzheimer's disease (AD) often present at a younger age with predominantly non‐amnestic impairments and a more aggressive disease course. Historically, individuals with atypical presentations have not been included in large‐scale clinical trials, which typically focus on late‐onset, sporadic amnestic‐predominant AD. Consequently, treatment options and research efforts specific to atypical AD remain limited. The emergence of amyloid‐targeting therapies that slow disease progression underscores these challenges, as evidence supporting their efficacy in early‐onset amnestic and non‐amnestic AD variants is scarce. This perspective article argues that atypical AD represents an excellent disease model for clinical trials and proposes strategies to address critical gaps in clinical trial design for this population. Key considerations include optimizing participant selection approaches, establishing syndrome‐specific or surrogate biological and clinical endpoints, and fostering advocacy to enhance early and accurate diagnosis, equitable representation, and outcomes for these populations.
O60 Icotrokinra, a targeted oral peptide that blocks IL-23 receptor activation, in moderate-to-severe ulcerative colitis: week 12 results from ANTHEM-UC
Limdi, Jimmy, Abreu, M T, Siegmund, Britta, Surace, Lindsey, Erondu, Ngozi, Chen, Minhu, Chachu, Karen, Louis, Edouard, Matsuoka, Katsuyoshi, Houck, Nicole, Frustaci, Mary Ellen, Zou, Bin, Rydzewska, G, Loftus, Edward V, Jairath, Vipul, Siegmund, Britta, Erondu, Ngozi, Chachu, Karen A., Matsuoka, Katsuyoshi , Arthur, Edmund, Frustaci, Mary Ellen, Zou, Bin , Rydzewska-Wyszkowska, Grażyna , Loftus, Edward V , Jairath, Vipul

Mayo Clinic

Oral Abstracts | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A38-A39

10.1136/gutjnl-2026-bsg.59 Get It

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia
Olzinski, Molly, Downer, Joshua, Rajbanshi, Binita, Li, Jingyao, Loureiro, Joseph, Heuer, Hilary, Ljubenkov, Peter, Vandevrede, Lawren, Staffaroni, Adam, Lario‐Lago, Argentina, Leichter, Dana, Wolf, Amy, Wise, Amy, Sanderson-Cimino, Mark, Barragan, Eden, Spina, S, Grinberg, Lea T., Seeley, William W., Casaletto, Kaitlin B., Kramer, Joel, Ramos, Eilana, Geschwind, Daniel, Cook, Casey, Petrucelli, L, Forsberg, Leah K., Gendron, Tania, Boeve, Bradley F., Rademakers, Rosa, Rosen, Howard J., Saloner, Rowan, Boxer, Adam L., Rojas, Julio C., Abdullah, M. Samy, Apostolova, Liana, Appleby, Brian, Bayram, Ece, Hp, Botha, Bozoki, Andrea, Brushaber, Danielle, Clark, David, Considine, Ciaran M., Darby, R. Ryan, Day, Gregory S., Dickerson, Bradford C., Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily, Faber, Kelley M., Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana, Galasko, Douglas R., Gavrilova, Ralitza, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Cn, Hales, Honig, Lawrence S., Gd, Hsiung, Huey, Edward D, Irwin, David, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler , Kornak, J M, Kremers, W., Kwan, Justin , Lapid, Maria, Lee, Suzee, Litvan, Irene, Lucente, Diane, Mackenzie, Ian R., Masdeu, J C, Massimo, Lauren, McGinnis, Scott, McMillan, Corey T., Mendez, Mario F., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pantelyat, Alexander, Pascual, Belen, Paulson, Henry, Ramanan, Vijay, Rankin, Katherine P., Rascovsky, Katya, Rhoads, Kristoffer , Savica, Rodolfo, Snyder, Allison, Sullivan, A. Campbell, Syrjanen, Jeremy, Tartaglia, M, Taylor, Jack, Tipton, P E, WEINTRAUB, S, Wint, Dylan, Wong, Bonnie, Yokoyama, Jennifer, Paulson, Henry L. , Barmada, Sami J. , Paulson, Henry L , Barmada, Sami , Cobigo, Yann , Worringer, Kathleen A. , Heuer, Hilary W. , VandeVrede, Lawren , Staffaroni, Adam M. , Wolf, Amy , Wise, Amy B. , Sanderson‐Cimino, Mark , Barragan, Eden V. , Grinberg, Lea T. , Seeley, William W. , Casaletto, Kaitlin B. , Kramer, Joel, Ramos, Eliana Marisa , Geschwind, Daniel H. , Forsberg, Leah K. , Gendron, Tania F. , Boeve, Bradley F. , Perneel, Jolien , Rademakers, Rosa , Rosen, Howard J. , Saloner, Rowan , Boxer, Adam L. , Rojas, Julio C. , Appleby, Brian S. , Barmada, Sami, Bayram, Ece , Botha, Hugo, Bozoki, Andrea C , Brushaber, Danielle , Clark, David, Considine, Ciaran , Dickerson, Bradford Clark , Dickson, Dennis, Domoto‐Reilly, Kimiko , Dwosh, Emily , Foroud, Tatiana, Graff‐Radford, Jonathan , Graff-Radford, Neill, Hales, Chadwick M., Honig, Lawrence S. , Hsiung, Ging-Yuek R., Huey, Edward D. , Jones, David T., Kantarci, Kejal , Kornak, John , Kremers, Walter, Kwan, Justin, Léger, Gabriel C. , Litvan, Irene , Lucente, Diane , Mackenzie, Ian R. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T. , Mendez, Mario F. , Mester, Carly , Pascual, Belén , Ramanan, Vijay, Rankin, Katherine P. , Roberson, Erik D. , Savica, Rodolfo , Snyder, Allison , Sullivan, A. Campbell , Syrjanen, Jeremy A. , Taylor, Jack C. , Tipton, Philip W., Vandebergh, Marijne , Weıntraub, Sandra , Wint, Dylan

Mayo Clinic

JAMA Neurology | June 22, 2026 | Volume: 83 | Issue: 8 | Pages: 778

10.1001/jamaneurol.2026.1927 | PMID 42329632 Get It

Importance TMEM106B is a frontotemporal lobar degeneration (FTLD) genetic susceptibility factor, and TMEM106B protein aggregates are a feature of aging and neurodegeneration. Whether TMEM106B protein levels are associated with clinical features is unknown. Objective To investigate the clinical associations of cerebrospinal fluid (CSF) TMEM106B in FTLD. Design, Setting, and Participants This cross-sectional study was conducted in 2 independent frontotemporal dementia (FTD) cohorts (recruitment from April 2009 through July 2023, with analyses from January 2025 through April 2026), with a 2-year follow up. This multicenter clinical study integrated clinical, genetic, biomarker, and neuroimaging data. Individuals were recruited through the University of California, San Francisco (n = 3733), or ALLFTD (n = 2343). Participants with available CSF were included. A discovery cohort (n = 271) included participants with sporadic neuropathology-confirmed FTLD; presymptomatic or symptomatic carriers of pathogenic variants in C9orf72 , GRN , or MAPT ; or controls. An independent validation cohort (n = 383) included participants with clinically diagnosed sporadic FTD, Alzheimer disease (AD), and controls. Exposures CSF samples for TMEM106B quantification with aptamer proteomics (SomaScan version 3.0 [discovery cohort] and SomaScan version 4.1 [validation cohort]). Main Outcomes and Measures Parametric tests compared the primary outcome, CSF TMEM106B, by disease severity, TMEM106B rs1990622 genotype, sex, clinical syndrome, pathological diagnosis, and pathogenic variant and determined associations with brain volume. Results In the discovery (n = 271; 136 women [51%]; median [IQR] age, 59 [38-80] years) and validation (n = 383; 183 women [48%]; median [IQR] age, 64 [50-78] years) cohorts, lower CSF TMEM106B was associated with more severe disease (β, −0.15; 95% CI, −0.24 to −0.04; P = .003), lower frontotemporal brain volumes (β, 0.42; 95% CI, 0.24-0.61; P < .001), and faster clinical progression (β, −2.21; 95% CI, −3.70 to −0.72; P = .001). Associations of TMEM106B with clinical disease severity were independent of those with neurofilament light chain. TMEM106B levels were influenced by TMEM106B rs1990622 genotype, where individuals with the protective G/G genotype had lower levels than the risk A/A genotype. CSF TMEM106B levels did not differentiate between FTLD subtypes or between FTLD and AD. Conclusions and Relevance Per the results of this cross-sectional study, TMEM106B is detectable in CSF and levels reflect disease severity in sporadic and genetic FTLD and AD, but levels are also influenced by the TMEM106B rs1990622 genotype. CSF TMEM106B could support further studies to understand the mechanisms of disease and develop clinical tools in FTLD and other neurodegenerative diseases.
Correlation of Serotonin Release Assay Positivity With  ELISA OD Value and Impact on the Management of Patients Suspected With HIT
Ianosi‐Irimie, Monica, Aljuboori, Omar , Edmonston, Tina Bocker, Worfolk, Laura A., Bi, Caixia , Tong, Carmen , Noh, Lina J., Espinoza, Andrew, Sahud, Mervyn A. , Dlott, Jeffrey S., Racke, Frederick K., Wong, Edward C.C. , Ianosi-Irimie, Monica, Edmonston, Tina Bocker , Racke, Frederick Karl

Mayo Clinic

International Journal of Laboratory Hematology | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/ijlh.70176 | PMID 42316906 Get It